Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 Gel to Clinically Noninfected Chronic Diabetic Foot Ulcers (cDFU)

NCT05276401 is registered in ClinicalTrials.gov with Lakewood-Amedex Inc as lead sponsor.

NCT NCT05276401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05276401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 Gel to Clinically Noninfected Chronic Diabetic Foot Ulcers (cDFU)
Lead sponsor
Lakewood-Amedex Inc
Phase
Phase 2
Overall status
Terminated
Start date
March 11, 2022
Completion date
June 15, 2022
Enrollment
3 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic diabetic foot ulcers